SCIENTISTS have programmed stem cells to grow new arthritis-fighting cartilage on a scaffold shaped like the ball of a hip joint.
Gene therapy was used to cause the cells to release anti-inflammatory molecules which fend off arthritis.
The technique may one day provide an alternative to hip replacement surgery, say the US researchers.
Patients could be receiving the living tissue replacement hip joints in as little as three years.
Professor Farshid Guilak, who led the Washington University team, said: “We’ve developed a way to resurface an arthritic joint using a patient’s own stem cells to grow new cartilage, combined with gene therapy to release anti-inflammatory molecules to keep arthritis at bay.
“Our hope is to prevent, or at least delay, a standard metal and plastic prosthetic joint replacement.”
Conventional prosthetic hip joints typically last for fewer than 20 years. A second operation to replace an artificial joint can destroy bone and risk infection.
For this reason, doctors are reluctant to carry out hip replacement surgery on patients younger than 50.
Dr Bradley Estes, vice-president of research and development at US biotech company Cytex Therapeutics Inc, which holds patents on the technology, said: “We envision in the future that this population of younger patients may be ideal candidates for this type of biological joint replacement.”
The new technique involves building a 3D biodegradable synthetic scaffold moulded into the precise shape of an individual hip joint.
Cartilage made from the patient’s own stem cells, taken from fat beneath the skin, resurfaces the hip joint with living tissue.
The cartilage is grown in a “weaving pattern” that makes the implant strong enough to withstand loads of up to 10 times a patient’s body weight. A gene is also inserted into the newly grown tissue and then activated with a drug to orchestrate the release of anti-inflammatory molecules.
“When there is inflammation, we can give a patient a simple drug, which activates the gene we’ve implanted, to lower inflammation in the joint,” said Prof Guilak. “We can stop giving the drug at any time, which turns off the gene.”
The scientists have tried out the technique on a simulated hip joint and are now testing the implants in laboratory animals.
Guilak said he expected the first human trials to take place in three to five years.
The research is described in the journal Proceedings of the National Academy of Sciences.
Why are you making commenting on The National only available to subscribers?
We know there are thousands of National readers who want to debate, argue and go back and forth in the comments section of our stories. We’ve got the most informed readers in Scotland, asking each other the big questions about the future of our country.
Unfortunately, though, these important debates are being spoiled by a vocal minority of trolls who aren’t really interested in the issues, try to derail the conversations, register under fake names, and post vile abuse.
So that’s why we’ve decided to make the ability to comment only available to our paying subscribers. That way, all the trolls who post abuse on our website will have to pay if they want to join the debate – and risk a permanent ban from the account that they subscribe with.
The conversation will go back to what it should be about – people who care passionately about the issues, but disagree constructively on what we should do about them. Let’s get that debate started!
Callum Baird, Editor of The National
Comments: Our rules
We want our comments to be a lively and valuable part of our community - a place where readers can debate and engage with the most important local issues. The ability to comment on our stories is a privilege, not a right, however, and that privilege may be withdrawn if it is abused or misused.
Please report any comments that break our rules.
Read the rules here